Close Menu

NEW YORK (GenomeWeb) – Contextual Genomics and the Personalized Medicine Initiative today announced that ArcherDx has joined the Canadian National Access Project for Cancer Testing.

ArcherDx's gene fusion assays will be used to help identify lung cancer gene mutations, Contextual Genomics CEO Chris Wagner said in a statement. ArcherDx's FusionPlex technology can detect EML4-ALK gene fusions and will "enhance our cancer panel tests to identify this mutated gene fusion in lung cancer patients," he said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.